Full-Time

Fixed Income Risk Analyst

Fixed Income

Updated on 7/11/2026

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

$90k - $180k/yr

+ Discretionary Corporate Bonus + Incentives

Company Historically Provides H1B Sponsorship

Boston, MA, USA + 1 more

More locations: London, UK

Hybrid

Hybrid role: 4 days in office per week, 1 day remotely.

Category
Finance & Banking (1)
Required Skills
Risk Management
Fixed Income Securities

People at Wellington Management

People at Wellington Management who can refer or advise you

Requirements
  • 3+ years’ experience in risk management within long only or benchmark-relative fixed income or multi-asset portfolios. This may have been gained on the Buy-side, the Sell-side or Consultancy
  • Proven ability to partner with investment talent effectively
  • Ability to manage multiple tasks, prioritize effectively, meet deadlines, and deliver high quality, accurate work in a fast-paced business
  • Demonstrable fixed income derivatives knowledge
Responsibilities
  • Interact directly with portfolio management teams alongside Risk Strategists, providing complementary insights and constructive challenge to investors on their investment theses and portfolio composition in support of superior risk-adjusted outcomes for clients.
  • Take increasing levels of responsibility for key aspects of assigned risk engagements. Proactively and creatively work to enhance these engagements by leveraging any unique insights from the Risk Analyst’s own experience with input from more senior risk professionals.
  • Conduct ad-hoc research and analysis to address investor questions and support the engagements of Risk Management.
  • Engage daily with Risk Strategists and investment professionals to ensure transparent measurement and reporting of risks in portfolios. Ensure dashboard, reports, or other shared tools are accurate and timely, and escalate concerns and observations of interest appropriately.
  • Partner with Line Management and Investment Products and Fund Strategies colleagues to ensure the firm’s fiduciary needs on investment risk are met.
  • Participate actively in Risk Meetings with Portfolio Strategists, group meetings within Global Risk and Performance Strategy, and other dialogues on market and portfolio risk insights, risk concerns and measurements.
  • Actively engage in enhancing the Risk reporting infrastructure, including design of exhibits and reports to support the risk oversight process.
Desired Qualifications
  • Prior experience in Risk Management roles is desirable but demonstrated quantitative or programming expertise coupled with experience in front-office facing roles such as trading, credit analysis, or portfolio management support positions would be considered
  • Strong academic credentials: post-graduate degree in a quantitative field and/or FRM/CFA/CAIA preferred
  • Experience with structured fixed income products such as Mortgage-Backed Securities (MBS) or Collateralized Loan Obligation (CLO) products would be considered a plus
  • Experience with risk models and/or data visualization tools is considered a plus
  • Knowledge of corporate credit, structured credit, or agency mortgage risk would be favorably considered
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$63.1B

Headquarters

Boston, Massachusetts

Founded

1933

People at Wellington Management

People at Wellington Management who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • $67M lead investment in Climate First Bank positions Wellington ahead of its potential IPO.
  • Dedicated private climate team expands into food, agriculture, and industrial automation sectors.
  • $90K-$180K Associate hire signals strong growth in Wellington's climate venture strategy.

What critics are saying

  • Passive ESG index funds compress fees, eroding AUM revenue by 5-8% annually within 12-18 months.
  • Climate First Bank IPO failure could trigger $200M+ AUM loss and client mandate withdrawals in 6-12 months.
  • EU reclassifies nonconcessionary climate strategies as high-risk, forcing disclosures and client exits in 9-15 months.

What makes Wellington Management unique

  • Wellington leads climate innovation with $385M first fund focused on tech-enabled climate solutions.
  • The firm uses proprietary CERA tool for geospatial analysis of physical climate risks against client assets.
  • Wellington offers differentiated private climate investing targeting adaptation and mitigation across energy and agriculture.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.